# Study Comparing STR (Skeletal Targeted Radiotherapy) Plus Melphalan to Melphalan Alone, With Stem Cell Transplant in Multiple Myeloma

> **NCT00083564** · PHASE3 · TERMINATED · sponsor: **Poniard Pharmaceuticals** · enrollment: 240 (—)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** STR(TM) (Skeletal Targeted Radiotherapy, Holmium-166-DOTMP)

## Key facts

- **NCT ID:** NCT00083564
- **Lead sponsor:** Poniard Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-03
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 240 (—)
- **Why stopped:** For business reasons
- **Last updated:** 2009-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00083564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00083564, "Study Comparing STR (Skeletal Targeted Radiotherapy) Plus Melphalan to Melphalan Alone, With Stem Cell Transplant in Multiple Myeloma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00083564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*